Pharma compliance in Pakistan runs through the same regulator as healthcare — the Drug Regulatory Authority of Pakistan — but the cybersecurity angle is different. For pharmaceutical manufacturers, the real exposure is GxP data integrity: the accuracy, completeness, and auditability of manufacturing, quality, and pharmacovigilance records, not just perimeter security.
Mutex Systems supports pharmaceutical manufacturers and distributors in Pakistan with GxP-aligned data-integrity controls and IT audits — an underserved niche adjacent to DRAP's registration and marketing-authorisation mandate, with no dedicated cyber-audit panel yet in place.
Every regulator with real jurisdiction over pharma in Pakistan, what they actually require, and where the audit-firm empanelment opportunity or existing engagement stands.
Drug Regulatory Authority of Pakistan
Not registered — opportunity
Named instruments, not vague policy statements — sourced from official regulator publications.
MoITT
Applies to: All public & private sector organisations nationally, including pharmaceutical manufacturers
Requires: National cyber-governance baseline that pharma manufacturers fall under in the absence of a DRAP-specific IT or data-integrity rule
Read the official sourceParliament / Ministry of Interior
Applies to: All persons and entities in Pakistan, including pharmaceutical manufacturers and distributors
Requires: Criminalises unauthorised access and data manipulation — relevant to protecting manufacturing, quality, and pharmacovigilance records from tampering
Read the official sourcegrComply applies the same Healthcare tenant-custom-framework approach with GxP-specific custom fields added through the Dynamic Schema Engine, so data-integrity evidence is tracked even without a DRAP-issued cyber framework to map against.
GxP (Good "x" Practice — covering Good Manufacturing Practice, Good Laboratory Practice, and related standards) data integrity refers to the accuracy, completeness, consistency, and auditability of manufacturing, quality, and pharmacovigilance records. For pharmaceutical manufacturers regulated by DRAP, protecting the integrity of these electronic records — not just perimeter network security — is the sharper compliance exposure, since falsified or corrupted records can affect drug safety and DRAP registration status.
No dedicated cyber or IT audit-firm panel has been identified for DRAP as of this research pass. DRAP's core mandate covers registration, marketing authorisation, manufacturing licensing, and pharmacovigilance under the DRAP Act 2012. GxP-aligned IT and data-integrity audits are an adjacent, currently underserved compliance area rather than an explicit DRAP-mandated requirement.
They share the same regulator — DRAP — but the practical compliance focus differs. Healthcare compliance centres on patient data protection across hospitals and telehealth platforms. Pharma compliance centres on GxP data integrity across manufacturing, quality, and pharmacovigilance systems — batch records, audit trails, and electronic signatures rather than patient-facing data.
Weak data-integrity controls create risk both operationally and regulatorily — corrupted or falsified manufacturing and quality records can affect drug safety decisions and DRAP registration or licensing status. Beyond DRAP's own oversight, tampering with electronic records can also fall under the Prevention of Electronic Crimes Act 2016 (PECA) as unauthorised data manipulation.
Yes. Mutex Systems supports pharmaceutical manufacturers and distributors in Pakistan with GxP-aligned IT audits and data-integrity controls covering batch-record systems, audit-trail completeness, and electronic-signature controls — structured around DRAP's mandate even in the absence of a DRAP-issued cyber framework.
Send us a short brief — your current posture, which regulator you answer to, and any inspection or audit deadline. Within two working days you will receive a written response and a proposed scoping call.